AstraZeneca head of vaccines and immunotherapies Eskra Rick explained: "We have a lot of data that showed that AstraZeneca vaccine is anti-omicron."

The company's senior official said that the Corona virus vaccine, produced by the company, could counter the omicron mutant that is currently most prevalent in the world.

Regarding the safety of the AstraZeneca vaccine for children, she said: "The data we have confirmed the vaccine's safety for children, and we will continue to collect more data. Now we discuss with regulars and through research, how we can provide it to children. "

On the other hand, Rick said that the company had achieved "record" results during 2021, confirming its commitment to provide the corona vaccine to the poorest countries to cope with the spread of the virus.

She added: "Proud of the results we have announced, 2021 was a record for AstraZeneca, and we expect these trends to continue in 2022 due to the innovative medicines we provide to markets."

She continued: "We focus very much on efforts to combat the Corona virus, and we will also provide the vaccine worldwide," she said, noting that the company has provided more than 2 billion 500 million doses of its vaccine around the world.

Rick stressed that "two thirds of these doses were sent to poorer countries."

The official at AstraZeneca pointed out that the company had committed to selling the vaccine at a cost price, so that it could be awarded to the largest number of people, especially in poor countries, and stressed that the company was "proud" of this decision, although it reduced its profits.

With regard to her prediction of when the Corona pandemic would end, she said that it was unpredictable, but stressed that it was necessary to provide the vaccine "to the greatest number of people, especially those without access to it, so that we can return to normal life."

AstraZeneca had declared that it had "fulfilled its promise to reach its Corona vaccine in a broad and fair manner, while providing 2 billion and 500 million doses of the vaccine, distributed worldwide."

The company expected revenues during the current year to rise by 13 to 19 percent, benefiting from increased vaccine deliveries.

In 2021, AstraZeneca's revenue grew by 41 percent.